Antiva raises $16M; RegeneRx takes dry eye gene therapy into PhII;

@FierceBiotech: Scripps team finds a drug that fights addiction by eliminating memories. FierceBiotechResearch story | Follow @FierceBiotech

@JohnCFierce: What's + PhII data from a small allergy study worth? Aimmune bags $160M IPO as the market continues to embrace bio. Article | Follow @JohnCFierce

@DamianFierce: "IPO (n.): An acronym for 'initial public offering' that neglects to mention the taking." More | Follow @DamianFierce

> Menlo Park, CA-based Antiva Therapeutics raised $16 million in a Series B round led by Canaan Partners and Sofinnova. The money is earmarked for an early-stage study of ABI-1968 for HPV infections. Release

> Gene therapy outfit RegeneRx Biopharmaceuticals is plotting to launch a Phase II trial of its treatment for dry eye in the U.S. next month following positive feedback from the FDA, the company said. More

> Amgen ($AMGN) has signed a deal with Indian drug giant Dr. Reddy's Laboratories to get its antibodies into the country. News

Medical Device News

@FierceMedDev: DNAnexus teams up with FDA for Precision Medicine cloud-based genomics platform. More from FierceDiagnostics | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Intuitive awards grants to support training of its da Vinci robot using virtual reality. Article | Follow @VarunSaxena2

@EmilyWFierce: A little news on CEO compensation. More from the WSJ | Follow @EmilyWFierce

> Global tech organization reveals new system for blood glucose monitoring devices. Story

> Medtronic recalls CoreValve TAVR component due to presence of particulate matter. News

> Miniature surgical robot startup gets $11M to assess feasibility in colon resection. Article

Pharma News

@FiercePharma: ICYMI yesterday: FDA updates label for Novartis' MS pill Gilenya after reports of brain infection. Article | Follow @FiercePharma

@EricPFierce: Aprecia is building $25M plant where it will do 3D printing of drugs. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: Perrigo CEO: Think Mylan's buyout will come easily? Think again. More | Follow @CarlyHFierce

> British watchdog cracks down on Pfizer for huge price hikes on epilepsy drug. Story

> Novo Nordisk beats in Q2 even as U.S. pricing pressures bite. Article

Vaccines News

> U.K's Prokarium scores $585,000 for oral chlamydia vaccine. Report

> State vaccination laws impact outbreak rates, study finds. Item

> Merck Ebola vaccine posts 100% efficacy in PhIII. More

> Novavax reports PhII success for quadrivalent seasonal flu vax. Story

> CSL completes purchase of Novartis' flu vaccine business. Article

CRO News

> Quintiles' $950M IPO keeps on giving for PE backers. Report

> Icon gets in on the ground floor with a Novartis-backed biotech upstart. More

> Patheon signs up to manufacture Flexion's lead drug. Item

> Parexel returns to growth after a shaky quarter. Story

> INC raises its 2015 expectations after another strong quarter. Article

Pharma Manufacturing News

> India, mad over EU ban on drugs, postpones trade talks. Item

> AMRI's expansion binge pays off for CMO. Story

> FDA warning letter smacks Indian lab for repeated shortcomings. More

> French regulator found 30 cases of mold contamination in biotech plant. Report

> GSK moves foward in Bangalore with new Indian plant. Article

Pharma Asia News

> India defers EU trade talks as ban on GVK-tested drugs rankles. Item

> China-focused Mabtech licenses four mAB candidates to Sorrento. More

> BeiGene receives first China trial approval nod for BGB-283. Story

> GSK rehires former China government affairs director Shi. Report

> AstraZeneca stands out again in China, hails AZD9291 in Japan. Article